Business Context and Reporting Period
This Form 8-K Current Report was filed by 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) on September 12, 2023, regarding events occurring on September 11, 2023. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and transition details.
Material Changes
- Departure of CFO: August J. Moretti retired as Chief Financial Officer and Assistant Secretary effective September 11, 2023. The retirement is not due to any disagreement with the Company or Board.
- Transition Role: Mr. Moretti will serve as a Senior Business Advisor through the end of 2023 and as a consultant through December 31, 2024.
- Appointment of New CFO: Uneek Mehra was appointed as Chief Financial and Business Officer, Principal Financial Officer, Principal Accounting Officer, and Assistant Secretary, effective September 11, 2023.
Compensation, Outlook, and Risks
Compensation Arrangements
August J. Moretti (Outgoing):
- Consulting retainer of $18,000 per month through December 31, 2024.
- Acceleration of remaining unvested stock options, subject to execution of a general release agreement.
Uneek Mehra (Incoming):
- Annual base salary: $510,000.
- Discretionary annual performance bonus target: 45% of base salary.
- Stock option grant: 229,634 shares of common stock.
- Sign-on bonus: $200,000 total, payable in two equal installments (first shortly after start, second after one year), subject to continued employment.
- Severance: Nine months of base salary plus COBRA reimbursement for up to nine months upon termination without cause or for good reason.
- Change in Control: Full vesting acceleration of equity awards if terminated without cause or for good reason within one month before or 12 months after a change in control.
Risks and Contingencies
Compensation benefits for both executives are conditioned on the execution of a general release agreement and continued compliance with the Company's Confidential Information and Invention Assignment Agreement. The filing states there are no family relationships between Mr. Mehra and other directors or officers.
Investor Verification Checklist
- Verify the exact vesting schedule and acceleration terms for Mr. Moretti's remaining stock options.
- Confirm the specific payment dates for Mr. Mehra's sign-on bonus installments.
- Review the Company's subsequent filings for the appointment of an interim CFO if Mr. Mehra's start date was delayed (though the filing states he joined effective Sept 11).
- Monitor future 10-Q or 10-K filings for the impact of these compensation changes on the Company's cash burn rate and stock-based expense.